MIM
ENTA icon

Monashee Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Monashee Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50,000
Closed -$4.78M – 174
2019
Q1 		$4.78M Buy
+50,000
New +$4.49M 1.1% 26

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Monashee Investment Management's ENTA Position: Q2 2019 in Review

Monashee Investment Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2019, closing a stake of 50,000 shares — an estimated $4.78M sold.

Monashee Investment Management first reported a position in ENTA in Q1 2019 and held it in 1 quarter. The position peaked at $4.78M in Q1 2019. 194 funds tracked by Wall St. Rank hold ENTA as of Q2 2019.

  • Monashee Investment Management reported no remaining Enanta Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Monashee Investment Management sold 50,000 Enanta Pharmaceuticals shares in Q2 2019, an estimated $4.78M.
  • Monashee Investment Management first reported a position in Enanta Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Monashee Investment Management's Enanta Pharmaceuticals position peaked at $4.78M in Q1 2019.
  • 194 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2019.

Based on Monashee Investment Management's 13F filing for Q2 2019, filed 7 Aug 2019.